Sigma-1 Receptor Antagonist (BD1047) Decreases Cathepsin B Secretion in HIV-Infected Macrophages Exposed to Cocaine.
Animals
Apoptosis
Brain
/ pathology
Caspase 3
/ biosynthesis
Cathepsin B
/ metabolism
Cell Line
Cocaine
/ pharmacology
Ethylenediamines
/ pharmacology
Female
HIV Core Protein p24
HIV Infections
/ metabolism
Humans
Immunohistochemistry
Macrophages
/ drug effects
Mice
Mice, Inbred ICR
Morpholines
/ pharmacology
Receptors, sigma
/ agonists
Young Adult
Sigma-1 Receptor
Cathepsin B
Cocaine
HAND
HIV-1
Sigma-1 receptor
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
ISSN: 1557-1904
Titre abrégé: J Neuroimmune Pharmacol
Pays: United States
ID NLM: 101256586
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
18
11
2016
accepted:
26
08
2018
pubmed:
12
10
2018
medline:
12
9
2020
entrez:
12
10
2018
Statut:
ppublish
Résumé
Pathogenesis of HIV-associated neurocognitive disorders (HAND) is mediated through the infiltration of perivascular macrophages into the brain with the secretion of viral, neurotoxic and inflammatory proteins. One of these proteins is cathepsin B (CATB), a lysosomal cysteine protease that induces neuronal apoptosis, and increases in plasma and cerebrospinal fluid from HIV-1 infected patients (Cantres-Rosario et al. AIDS 27(3):347-356, 2013). Cocaine further potentiates CATB neurotoxicity in vitro and in vivo (Zenón et al. J NeuroImmune Pharmacol 9(5):703-715, 2014). Modulation of sigma-1 (Sig1R) by cocaine increases oxidative species, cytokines and other factors that promote lysosomal disruption. However, the role of Sig1R in CATB secretion and HIV-1 replication in macrophages exposed to cocaine is unknown. We hypothesized that pharmacological modulation of Sig1R would alter CATB secretion from HIV-1 infected macrophages in vitro and in vivo. To test our hypothesis, monocyte derived-macrophages (MDM) from HIV-1 seronegative donors were isolated, infected with HIV-1
Identifiants
pubmed: 30306495
doi: 10.1007/s11481-018-9807-4
pii: 10.1007/s11481-018-9807-4
pmc: PMC6488453
mid: NIHMS1009238
doi:
Substances chimiques
Ethylenediamines
0
HIV Core Protein p24
0
Morpholines
0
Receptors, sigma
0
2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate
138847-85-5
N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin
1S3X75QGDO
CASP3 protein, human
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Cathepsin B
EC 3.4.22.1
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-240Subventions
Organisme : NIMH NIH HHS
ID : R24 MH059724
Pays : United States
Organisme : NIMH NIH HHS
ID : U24 MH100931
Pays : United States
Organisme : NIDA NIH HHS
ID : R13 DA023184
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA041018
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007587
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS043011
Pays : United States
Organisme : NINDS NIH HHS
ID : R24 NS038841
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH083501
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM113691
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG043540
Pays : United States
Organisme : NIMHD NIH HHS
ID : G12 MD007600
Pays : United States
Organisme : NIH HHS
ID : R24 OD018546
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007600
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH083500
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM061838
Pays : United States
Organisme : NIMH NIH HHS
ID : U24 MH100928
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH083506
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH083516
Pays : United States
Références
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7086-92
pubmed: 11416192
Am J Pathol. 2001 Dec;159(6):2045-54
pubmed: 11733355
J Leukoc Biol. 2005 Dec;78(6):1198-203
pubmed: 16204638
Int Immunopharmacol. 2006 Jun;6(6):1029-33
pubmed: 16644490
J Pharmacol Exp Ther. 2006 Dec;319(3):1355-65
pubmed: 16988055
Curr Pharm Des. 2007;13(4):387-403
pubmed: 17311556
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
Oncogene. 2008 Oct 27;27(50):6434-51
pubmed: 18955971
J Immunol. 1991 Jan 1;146(1):81-4
pubmed: 1984454
Blood. 2010 Jun 10;115(23):4951-62
pubmed: 20354174
Trends Pharmacol Sci. 2010 Dec;31(12):557-66
pubmed: 20869780
Blood. 2011 Feb 24;117(8):2538-47
pubmed: 21148086
Trends Immunol. 2011 Mar;32(3):110-6
pubmed: 21333600
Brain Res Bull. 2011 May 30;85(3-4):219-24
pubmed: 21453760
Biochim Biophys Acta. 2012 Jan;1824(1):22-33
pubmed: 21914490
PLoS One. 2012;7(5):e36571
pubmed: 22693552
AIDS. 2013 Jan 28;27(3):347-56
pubmed: 23291538
Neuropsychopharmacology. 2013 Dec;38(13):2588-97
pubmed: 23822950
Synapse. 2014 Feb;68(2):73-84
pubmed: 24123353
PLoS One. 2014 Jan 07;9(1):e85246
pubmed: 24409324
PLoS One. 2014 Aug 29;9(8):e106533
pubmed: 25171370
J Neuroimmune Pharmacol. 2014 Dec;9(5):703-15
pubmed: 25209871
Eur J Pharmacol. 2014 Nov 15;743:42-7
pubmed: 25261035
Mol Neurobiol. 2016 Mar;53(2):1329-42
pubmed: 25631712
Sci Rep. 2015 Mar 02;5:8670
pubmed: 25728014
AIDS. 2015 Oct 23;29(16):2081-92
pubmed: 26208400
Front Microbiol. 2015 Sep 08;6:931
pubmed: 26441868
J Drug Alcohol Res. 2016 Feb 20;5:
pubmed: 27088037
Sci Rep. 2016 Jun 20;6:27864
pubmed: 27321752
Cell Death Dis. 2016 Oct 13;7(10):e2414
pubmed: 27735948
Eur J Pharmacol. 1988 Apr 27;149(1-2):171-4
pubmed: 2840298
Oxid Med Cell Longev. 2017;2017:4582135
pubmed: 28883901
J Neuroimmune Pharmacol. 2018 Sep;13(3):345-354
pubmed: 29987592
Psychopharmacology (Berl). 1993;113(1):67-75
pubmed: 7862831
J Psychoactive Drugs. 1993 Jul-Sep;25(3):207-21
pubmed: 8258759
J Leukoc Biol. 1997 Jul;62(1):100-6
pubmed: 9226000
J Virol. 1998 Apr;72(4):3340-50
pubmed: 9525661
Adv Exp Med Biol. 1998;437:199-205
pubmed: 9666272